GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta Therapeutics’ Elevidys and Novartis’ ...
“The old transactional sales model does not work anymore.” Grant Leboff is not the first person to claim that the old ways of selling no longer work. Nor is Sales Therapy the first book to detail how ...
Avrobio (NASDAQ:AVRO) said it has completed the sale of its gene therapy program for the treatment of cystinosis to Novartis (NYSE:NVS) for $87.5M in cash, which should extend the biotech company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results